Skip to main content
. Author manuscript; available in PMC: 2022 May 28.
Published in final edited form as: Cancer Lett. 2021 Mar 6;506:95–106. doi: 10.1016/j.canlet.2021.03.002

Figure 1. IRF-1 upregulates CXCL10 expression in HCC cells.

Figure 1.

A) IRF-1 and CXCL10 mRNA expression are determined by qRT-PCR in tumor from HCC patients (n=10). B) Correlative analysis of IRF-1 and CXCL10 mRNA expression in HCC patients is based on TCGA database (n=360). Each data point (A & B) represents one patient. IRF-1 and CXCL10 mRNA expression are measured by qRT-PCR in Hepa1–6 cells (C, D) and Huh-7 (E, F) induced by mouse IFN-γ (50 u/ml) / human IFN-γ (100 u/ml) for 24 h, or infected by mouse / human AdIRF-1 (50 MOI) for 48 h, respectively. Each data point (C, D, E & F) represents an independent experiment (n=3–4). CXCL10 protein expression in cell lysis and culture supernatant are detected by ELISA in Hepa1–6 cells (G, I) and Huh-7 cells (H, J). The cells are infected by mouse / human AdIRF-1 (50 MOI) for 48 h (G, H). Cells are transfected with IRF-1 siRNA or negative control (NC) for 48 h with or without mouse IFN-γ (50 u/ml) / human IFN-γ (100 u/ml) for 12 h, respectively (I, J). ELISA assay data represent the means ± SEM of two samples and are representative of two independent experiments with similar results. The statistical analyses on four different groups (I, J) are performed by One-way ANOVA. The t test is used to compare between two different groups, *p<0.05, **p<0.01.